Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market.
Level 5 - mechanism / opinion, no new human data
Bench analytical chemistry study (Level 5 by clinical CEBM / non-human laboratory study)
PubMed 30029448 · doi:10.1016/j.talanta.2018.06.023
What was done
Researchers performed systematic impurity profiling of the ten most frequently encountered falsified peptide drugs on the Belgian market, sourced from three suspected illegal online pharmacies. The screening analyzed active pharmaceutical ingredient (API) content, API-related impurities, small-molecule contaminants, residual solvents, and elemental impurities, including arsenic speciation.
What was found
Samples exhibited wide variation in API content per unit and low purity, ranging from 5% to 75% for cysteine-containing peptides. Elemental analysis revealed contamination with Class 1 toxic metals: one sample contained lead (Pb), and multiple samples contained arsenic (As) at concentrations up to ten times the International Council for Harmonisation (ICH) toxicity limit for parenteral drugs. Speciation confirmed that all detected arsenic was present as toxic inorganic arsenic.
Why it matters
Falsified peptide biotherapeutics and doping agents sold online present severe health risks not only from unpredictable dosing and peptide impurities, but also from direct parenteral exposure to bioaccumulative and carcinogenic heavy metals.
Limits
The abstract does not state the total number of individual product batches or vials tested across the ten peptide drug types. Findings reflect specific illicit market samples sourced in Belgium and do not directly measure clinical or toxicological outcomes in human consumers.
Cited by
- supports Laboratory testing of gray-market and research peptide vials has revealed discrepancies such as impurities, endotoxins, and inaccurate concentrations.